An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.
Ahead of the institute’s annual forum that is set to take place this week, the HKGFA team shares its view of sustainability opportunity across HK and GBA.